InterMune's lung drug delays disease progression in trial
Feb 25 (Reuters) - InterMune Inc said its experimental lung drug reduced the progression of a disease that leads to loss of lung function in a late-stage trial.
The trial compared the drug, pirfenidone, with a placebo, and showed that after 52 weeks of treatment, 16.5 percent of patients in the pirfenidone group experienced disease progression, compared with 31.8 percent in the placebo group.
The disease, idiopathic pulmonary fibrosis (IPF), is an irreversible condition that leads to progressive loss of lung function due to scarring, which hinders the lungs' ability to absorb oxygen.
InterMune said it expected to submit a marketing application for the drug to the U.S. Food and Drug Administration by early third quarter of this year.
Trading in the company's shares was halted ahead of the announcement. They closed at $13.96 on the Nasdaq on Monday.
- Tesla says in talks with BMW over car batteries, parts
- Hagel, under pressure, resigns as defense secretary |
- Missouri grand jury has made decision in fatal shooting of black teen: report |
- Iran nuclear talks extended seven months after failing to meet deadline |
- Actor Dwight Henry eyed in New Orleans killing after arrest for theft
We are living longer but not creating financial plans to keep pace. Advisers give tips on how to make sure you don’t outlive your money. Video